Lonza becomes latest One Nucleus partner

Cambridge UK: 25 February 2019 - Lonza Biologics becomes the latest One Nucleus Partner. The Partner Program is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.

Sarah Holland, Global Head of Licensing at Lonza commented ‘Lonza has been a member of the One Nucleus ecosystem for a number of years. We are delighted to strengthen our relationship further by becoming a One Nucleus partner. We are committed to supporting innovation and see the building of strong relationships with biotechnology companies and research institutes as a key part of our strategy. We very much look forward to both interacting with new members and building on existing relationships’.

Tony Jones, CEO of One Nucleus expands further ‘In order for our sector to collectively deliver better outcomes to patients it is imperative that each part of the ecosystem is connected and performs to the best of its ability. Innovation in the supply chain, driven by such world leaders as Lonza, enables One Nucleus members developing new treatments to develop and manufacture their products in the optimal way. I am delighted Lonza have elected to become a Partner to enable strategic engagement with our members and wider network thereby ensuring their innovation and excellence is accessed whenever appropriate”

Click here for the full press release.

Media Contact Information: 

Laura Hicks - info@onenucleus.com